Competition protection and social orientation in the pharmaceutical market: Regional aspects

¹ Kaluga State University named after K.E. Tsiolkovski, 26, Stepan Razin str., Kaluga, 248023, Russia
² Institute of Management, Business and Technology, 1, Gagarin str., Kaluga, 248000, Russia

^* Corresponding author: vkkrutikov@mail.ru

Abstract

In the article the processes connected with the development of the domestic pharmaceutical market and the formation of biopharmaceutical and medical clusters, as well as the nuclear educational cluster in the Kaluga Oblast are studied. The results of the conducted scientific work allowed to formulate a number of features characterizing the modern pharmaceutical market: positive dynamics of development, state support of the competitive environment, reliance on innovative projection of digital technologies and the triple helix model, clearly expressed social function of providing the population with medicines. Proven long-term development prospects and effective results of the implementation of cluster policy, carried out within the framework of domestic and international trends, leading countries and companies of the world, integrating technological innovation (bioengineering, biotechnology, biomedicine). In recent years, the provisions of the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the period up to 2030 have been actively implemented. Kaluga Oblast is purposefully improving its activities on the formation of modern cluster policy, the priority direction of which is the development of the cluster of innovative pharmaceuticals, biomedicine, bioengineering and biotechnology. The creative orientation of nuclear and radiological scientists in their scientific research was not limited to narrow specialization, but made a breakthrough in pharmacology, medicine and biology. And innovative knowledge is brought to the stage of commercialization, objectively giving a new projection to the conditions of formation of the pharmaceutical market, which acquires features of constructive competition, creating socially oriented mechanisms of cost management, which leads to lower prices of medicines.